DDInter71 DDInter899
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Aminoglutethimide {u} (Compound) resembles {v} (Compound) Glutethimide
Aminoglutethimide {u} (Compound) binds {v} (Gene) CYP19A1
Aminoglutethimide {u} (Compound) is included by {v} (Pharmacologic Class) Adrenal Steroid Synthesis Inhibitors
Aminoglutethimide {u} (Compound) downregulates {v} (Gene) PSMB8
Aminoglutethimide {u} (Compound) causes {v} (Side Effect) Anaemia
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glimepiride
Aminoglutethimide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Aminoglutethimide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Aminoglutethimide {u} may lead to a major life threatening interaction when taken with {v} Lumateperone
Aminoglutethimide (Compound) resembles Glutethimide (Compound)
Aminoglutethimide (Compound) binds CYP19A1 (Gene)
Aminoglutethimide (Compound) is included by Adrenal Steroid Synthesis Inhibitors (Pharmacologic Class)
Aminoglutethimide (Compound) downregulates PSMB8 (Gene)
Aminoglutethimide (Compound) causes Anaemia (Side Effect)
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Glimepiride
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib
Aminoglutethimide may lead to a major life threatening interaction when taken with Lumateperone